Arlene Vogan

Arlene Vogan

Team Leader, Health Economics

School of Public Health

Faculty of Health and Medical Sciences

Arlene is a senior health economist in Adelaide Health Technology Assessment (AHTA), and has worked in the field of HTA for 10 years. She is responsible for the production or evaluation of economic evaluations of medical services, pharmaceuticals and co-dependent technologies for the Medical Services Advisory Committee and/or the Pharmaceutical Benefits Advisory Committee.

Arlene's research interests include health economics, health technology assessment and evidence based medicine.

  • Journals
    Year Citation
    2016 Carter, D. A., Vogan, A., & Haji Ali Afzali, H. (2016). Governments need better guidance to maximise value for money: the case of Australia’s Pharmaceutical Benefits Advisory Committee. Applied Health Economics and Health Policy, 14(4), 401-407.
    DOI Scopus14 WoS11 Europe PMC5

  • Conference Papers
    Year Citation
    2018 Carter, D. A., Vogan, A., & Merlin, T. (2018). The need for ethics committees and evaluation agencies in coverage with evidence development: the case of crizotinib in Australia. In Australasian Association of Bioethics and Health Law Conference. Townsville.

  • Conference Items
    Year Citation
    2019 Newton, S., Kessels, S., Vogan, A., & Merlin, T. (2019). Shift From Regional To Federal Funding: Methodological Considerations. Poster session presented at the meeting of XVI Annual Meeting, Health Technology Assessment international (HTAi). Cologne, Germany.
    2018 Milverton, J., Newton, S., Vogan, A., Schubert, C., & Merlin, T. (2018). Methodology to assess a predictive test for breast cancer recurrence. Poster session presented at the meeting of Abtracts of the Annual Meeting HTAi 2018. Vancouver, Canada: Health Technology Assessment international (HTAi).
    2018 Vogan, A., & Schubert, C. M. (2018). A COST-UTILITY ANALYSIS OF PROSIGNA®, A 50 GENE TEST FOR PREDICTING BREAST CANCER RECURRENCE, IN THE AUSTRALIAN SETTING. Poster session presented at the meeting of VALUE IN HEALTH. ELSEVIER SCIENCE INC.
    DOI
    2017 Vogan, A., Schubert, C., & Merlin, T. (2017). The Impact Of Treatment Timing On The Cost-Effectiveness Of Tests. Poster session presented at the meeting of the 14th Annual Health Technology Assessment international (HTAi) Conference. Rome, Italy.
    2016 Vogan, A., Schubert, C., Newton, S., & Merlin, T. (2016). What are we missing by limiting the outcome of cost effectiveness analyses of diagnostic tests to cost per correct result?. Poster session presented at the meeting of the 13th Annual Health Technology Assessment international (HTAi) Conference. Tokyo, Japan.
    2015 Vogan, A., Mitchell, A., Tamblyn, D., & Merlin, T. (2015). Managed Entry Schemes: Enabling Access To Oncology Drugs Under Uncertainty. Poster session presented at the meeting of the 12th Annual Health Technology Assessment international (HTAi) Conference. Oslo, Norway.
    2014 Vogan, A., Schubert, C., Parsons, J., Morona, J., & Merlin, T. (2014). The impact of an imperfect diagnostic reference standard on the cost-effectiveness of HbA1c testing in the diagnosis of Type II diabetes. Poster session presented at the meeting of the 11th Annual Health Technology Assessment international (HTAi) Conference. Washington D.C., USA.
    2014 Vogan, A., Schubert, C., Parsons, J., Morona, J., & Merlin, T. (2014). Assessing the cost-effectiveness of HbA1c testing in the diagnosis of Type II diabetes and the impact of an imperfect diagnostic reference standard. Poster session presented at the meeting of the 36th Annual North American Meeting Society for Medical Decision Making (SMDM). Miami, USA.

  • Report for External Bodies
    Year Citation
    2023 Milverton, J., Allani, P., Carter, D., Vogan, A., Newton, S., & Parsons, J. (2023). Newborn bloodspot screening for sickle cell disease and beta thalassaemia (MSAC Application 1737). Canberra, ACT.
    2022 Milverton, J., Demir, M., Carter, D., Hill, H., Parsons, J., Tamblyn, D., & Vogan, A. (2022). Genetic testing for children with hearing impairment (MSAC Application 1680). Canberra: Commonwealth of Australia.
    2022 Newton, S., Vogan, A., Lett, B., Liufu, Z., & Parsons, J. (2022). Small gene panel testing for non-squamous non-small cell lung cancer (MSAC Application 1721). Canberra: Commonwealth of Australia.
    2022 Newton, S., Allani, P., Salinger, K., Morona, J., Mittal, R., & Vogan, A. (2022). Whole genome sequencing of mycobacterium to identify antimicrobial-resistant pathogens (MSAC Application 1646). Canberra: Commonwealth of Australia.
    2020 Tamblyn, D., Vogan, A., Parsons, J., Schubert, C., Bellman, S., & Carter, D. (2020). Technical report to supplement clinical utility card for genetic testing for diagnosis of inheritable cardiomyopathies (MSAC Application 1599). Canberra: Commonwealth of Australia.
    2020 Tamblyn, D., Vogan, A., Parsons, J., Schubert, C., Bellman, S., & Carter, D. (2020). Clinical utility card for heritable cardiomyopathies.
    2019 Wyndham, A., Vogan, A., Newton, S., & Schubert, C. (2019). Immunoglobulin for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (MSAC application 1565). Commonwealth of Australia.
    2019 Kessels, S., Newton, S., Vogan, A., Mittal, R., Schubert, C., Carter, D., . . . Merlin, T. (2019). Clinical utility card for heritable mutations associated with familial hypercholesterolaemia (MSAC Application 1534). Canberra: Commonwealth of Australia.
    2019 Kessels, S., Newton, S., Vogan, A., Mittal, R., Schubert, C., Carter, D., . . . Merlin, T. (2019). Technical report to supplement clinical utility card for heritable mutations associated with familial hypercholesterolaemia (MSAC Application 1534). Canberra: Commonwealth of Australia.
    2018 Mittal, R., Kessels, S., Morona, J., Newton, S., Vogan, A., & Schubert, C. (2018). Heritable mutations which increase risk in colorectal and endometrial cancer - Lynch syndrome and adenomatous polyposis syndrome. Economic and financial evaluation. (MSAC clinical utility card 1504). Canberra: Commonwealth of Australia.
    2018 Milverton, J., Vogan, A., Newton, S., Parsons, J., Schubert, C., & Merlin, T. (2018). Extended half-life clotting factor concentrates for the treatment of haemophilia A and B (MSAC Application 1511).
    2018 Milverton, J., Vogan, A., Parsons, J., Kessels, S., Carter, D., Schubert, C., . . . Merlin, T. (2018). Genetic deletion testing for alpha thalassaemia (MSAC Application 1531). Canberra: Commonwealth of Australia.
    2017 Milverton, J., Vogan, A., Newton, S., Schubert, C., & Merlin, T. (2017). 50 gene signature assay for predicting breast cancer recurrence (MSAC Application 1473).
    2016 Morona, J., Vogan, A., Kessels, S., Newton, S., Pridham, L., Ellery, B., . . . Merlin, T. (2016). Magnetic resonance imaging of patients with suspected non-ischaemic cardiomyopathies (MSAC 1432). Canberra.
    2016 Morona, J., Kessels, S., Vogan, A., Mittal, R., Newton, S., Parsons, J., . . . Merlin, T. (2016). Cardiac MRI for myocardial stress perfusion and viability imaging in patients with known or suspected coronary artery disease (MSAC application number 1237). Canberra, ACT: Commonwealth of Australia.
    2016 Kessels, S., Mittal, R., Morona, J., Newton, S., Ellery, B., Milverton, J., . . . Merlin, T. (2016). Magnetic resonance imaging of patients with suspected (non-ischaemic) dilated cardiomyopathies (MSAC Application no. 1393). Canberra, ACT: Commonwealth of Australia.
    2015 Kessels, S., Morona, J., Mittal, R., Vogan, A., Newton, S., Schubert, C., & Merlin, T. (2015). Testing for hereditary mutations in the Cystic Fibrosis conductance Transmembrane Regulator (CFTR) gene (1216). http://www.msac.gov.au/internet/msac/publishing.nsf/Content/B1083E11E4A3006BCA257BCB0081849E/$File/1216-MSAC-CA-CFTR.pdf: Commonwealth of Australia.
    2014 Ellery, B., Milverton, J., Newton, S., Morona, J. K., Gum, D., Parsons, J., . . . Merlin, T. (2014). Retinal photography with a non-mydriatic retinal camera in people with diabetes (MSAC Application number 1181). Canberra, ACT.: Commonwealth of Australia.
    2014 Morona, J. K., Vogan, A., Kessels, S., Gum, D., Milverton, J., Parsons, J., . . . Merlin, T. (2014). Nucleic acid amplification testing for active mycobacterial infection (MSAC Application number 1234). Canberra, ACT.: Commonwealth of Australia.
    2014 Parsons, J., Vogan, A., Morona, J. K., Schubert, C., & Merlin, T. (2014). HBA1c test for the diagnosis of diabetes mellitus (MSAC Application 1267). Canberra, ACT.: Commonwealth of Australia.
  • Position: Team Leader, Health Economics
  • Phone: 83136898
  • Email: arlene.vogan@adelaide.edu.au
  • Campus: North Terrace
  • Building: 44-60 Rundle Mall - Rundle Mall Plaza, floor Level Four
  • Org Unit: Adelaide Health Technology Assessment
Connect With Me